New Delhi, Aug. 27 -- India's Contract Research, Development, and Manufacturing Organisation (CRDMO) sector, currently valued at around USD 3 billion, is set to grow rapidly in the coming years.

According to a report by Jefferies, the industry is expected to expand at an 18% compound annual growth rate (CAGR) from FY25 to FY30, outpacing the 14% growth seen over the past five years.

This growth is being driven by several key factors. Global pharmaceutical companies are increasingly adopting the "China+1" strategy, diversifying their supply chains to reduce dependence on China.

Additionally, rising demand for treatments targeting obesity and type 2 diabetes, along with advancements in antibody-drug conjugates (ADCs), is further boosting...